First Israel Mezzanine Investors completed the acquisition of a 90% stake in Rafa Laboratories for $195m.

First Israel Mezzanine Investors, a private equity investor, completed the acquisition of a 90% stake in Rafa Laboratories, a drug development company, for $195m. "The entry of FIMI as the senior partner and leader of Rafa will allow the continued operations of the factory in Jerusalem and the promotion of Rafa's business in Israeli and overseas markets. This is a significant day in the long history of the company," Amir Levin, Rafa CEO.